Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions, has opened its third Canadian Rapid Treatment Center of Excellence (“CRTCE”) clinic. Champignon chairman and CEO Roger McIntyre announced the opening of the center; the announcement noted that the clinics — the other two are located in Mississauga and Toronto — are focused on the treatment of depression and suicide through novel ketamine therapy treatment. The company noted in the announcement that more than 20 clinical trials have been conducted that demonstrate the effectiveness of ketamine and esketamine in treating patients who have failed to respond to conventional antidepressants. Champignon’s CRTCE clinics are the first of their kind in Canada. They specialize in providing breakthrough rapid onset treatments for depression including but not limited to intravenous ketamine and intranasal esketamine. “The opening of our first Ottawa CRTCE Clinic provides an opportunity for CRTCE to provide access to new treatments for people who are suffering from depression,” said Champignon chairman and CEO Roger McIntyre in the press release. “In addition to providing clinical care, all CRTCE Clinics conduct research that aims to improve the quality of people’s lives affected by these common and debilitating disorders in Canada.”
To view the full press release, visit https://ibn.fm/TRWqs
About Champignon Brands Inc.
Champignon Brands is focused on the formulation and manufacturing of novel ketamine, anesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mild traumatic brain injury (“mTBI”) with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.ChampignonBrands.com.
NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.